Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade - PubMed (original) (raw)

Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade

P C Mack et al. Prostate. 1998.

Abstract

Background: The RB1 proliferation control pathway is a critical determinant of cell cycle progression. Abnormalities of RB1 are found in a variety of cancers, and the association with human prostate cancer (CaP) was examined here.

Methods: RNA expression levels of RB1 in CaPs were examined by RT-PCR. RNA integrity was assessed by evaluating expression of an endogenous gene standard.

Results: Abnormally low RB1 mRNA expression was found in 12/33 (36%) of CaPs from patients who had received combined androgen blockade (CAB) treatment. In contrast, 6/48 (13%) untreated CaPs showed abnormally low expression. This difference was statistically significant (P = 0.015). In the samples from untreated patients, a higher frequency of abnormal RB1 was found in specimens with a higher Gleason grade (P = 0.038). In addition, one untreated stage C, grade 9 specimen was found to express RB1 transcripts lacking exon 22, as determined by sequencing of DNA from the truncated transcripts.

Conclusions: These findings suggest that abnormalities of RB1 may contribute to hormone-withdrawal-related survival of CaP cells.

PubMed Disclaimer

Cited by

RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy.
Indovina P, Pentimalli F, Casini N, Vocca I, Giordano A. Indovina P, et al. Oncotarget. 2015 Jul 20;6(20):17873-90. doi: 10.18632/oncotarget.4286. Oncotarget. 2015. PMID: 26160835 Free PMC article. Review.
miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas.
Shi L, Jiang D, Sun G, Wan Y, Zhang S, Zeng Y, Pan T, Wang Z. Shi L, et al. J Neurooncol. 2012 Nov;110(2):155-62. doi: 10.1007/s11060-012-0951-z. Epub 2012 Aug 14. J Neurooncol. 2012. PMID: 22886530
The AR dependent cell cycle: mechanisms and cancer relevance.
Schiewer MJ, Augello MA, Knudsen KE. Schiewer MJ, et al. Mol Cell Endocrinol. 2012 Apr 16;352(1-2):34-45. doi: 10.1016/j.mce.2011.06.033. Epub 2011 Jul 12. Mol Cell Endocrinol. 2012. PMID: 21782001 Free PMC article. Review.
Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence.
Chen JL, Li J, Stadler WM, Lussier YA. Chen JL, et al. J Am Med Inform Assoc. 2011 Jul-Aug;18(4):392-402. doi: 10.1136/amiajnl-2011-000178. J Am Med Inform Assoc. 2011. PMID: 21672909 Free PMC article.
E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo.
Sun H, Wang Y, Chinnam M, Zhang X, Hayward SW, Foster BA, Nikitin AY, Wills M, Goodrich DW. Sun H, et al. Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):704-9. doi: 10.1073/pnas.1015027108. Epub 2010 Dec 27. Proc Natl Acad Sci U S A. 2011. PMID: 21187395 Free PMC article.

Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade - PubMed (original) (raw)